Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03944772
Title Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca

lung adenocarcinoma


Necitumumab + Osimertinib

Osimertinib + Selpercatinib

Alectinib + Osimertinib

Carboplatin + Durvalumab + Pemetrexed Disodium

Osimertinib + Savolitinib

Gefitinib + Osimertinib

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | CAN

No variant requirements are available.